Introduction
threshold velocity (TTV), below which thrombotic occlusion is likely to occur. The purpose of an adjuvant High outflow resistance and low velocity of blood AVF is to accelerate blood flow in the graft above flow leading to thrombotic occlusion of the graft is a the TTV level by supplementing the limited run-off potential cause of early failure of femorodistal bypass provided by a severely diseased peripheral vascular surgery, especially when the indication is critical isch-bed. Although AVF has been employed, empirically, aemia. The alien flow surface presented by prosthetic as an adjunct to femorodistal bypass surgery since grafts renders them more prone to this complication the early 1980s, and improved results have been than grafts constructed from autologous veins and this claimed, 2-10 its value has not previously been evaluated may be a factor contributing to their comparatively in a controlled trial. poor performance. Sauvage 1 demonstrated exOne potential disadvantage of AVF is that the acperimentally that there is a characteristic velocity of celeration of blood flow, by promoting random turblood flow for all graft materials, the thrombotic bulence, may aggravate problems at the distal anastomosis due to myointimal hyperplasia (MIH). of all prosthetic femoro-infrapopliteal bypasses. Therefore, the aim of the trial reported here was to determine whether AVF provided any additional clinical advantage over interposition vein-cuff in patients having femoro-infrapopliteal bypass surgery for critical limb ischaemia.
Patients and Methods

Patients
The vascular surgical services of two U.K. teaching hospitals, Royal Liverpool University Hospital, Liver- Fig. 2 . Pre-anastomotic fistula.
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pool and Chelsea and Westminster Hospital, London, participated in this trial. form of Cefotaxime 1.5 gm intravenously at induction. A total of 89 femoro-infrapopliteal bypasses using Externally supported 6 mm ePTFE grafts (Impra Corp) ePTFE grafts, carried out in 87 patients with critical were employed in all cases. The distal anastomosis limb ischaemia, were included between June 1991 and was constructed in end-to-side manner with an inJune 1997. The mean age of the patients was 70.3 years terposition vein-cuff. 13, 14 (range 31-89 years) and the male to female ratio was A common ostium fistula ( Fig. 1 ) was constructed 3.2:1. Fourteen were diabetic and 57 admitted to smok-in patients in whom the concomitant veins related to ing within the last year. All had critical limb ischaemia the recipient artery were judged to be small, and a as defined by the European Consensus Document. 12 pre-anastomotic fistula ( Fig. 2 ) was used in those with Forty-eight were randomly allocated to receive an larger concomitant veins. In all cases the use of clamps adjuvant AVF and 41 to a control group. Clinical was avoided, prevention of back bleeding being characteristics of the patients in each group are shown achieved with fine intraluminal silicone catheters. in Table 1 . Local ethical committee approval was ob-Antiplatelet therapy in the form of aspirin 300 mg tained prior to the commencement of the trial. Patients, daily was commenced at least 48 h preoperatively. All who consented to take part, were recruited con-patients received heparin 5000 iu during operation secutively. Exclusion criteria were: (i) the presence of and anticoagulation was continued for 5 days after autologous vein suitable for vein graft; (ii) venous operation with a continuous infusion of heparin, the hypertension due to deep venous obstruction in the dose of which was adjusted to maintain APPT levels affected limb; (iii) severely compromised cardiac func-within a therapeutic range of 2-3 times normal value. tion.
All patients were discharged on oral warfarin in addition to the aspirin which had been commenced preoperatively, this anticoagulation regime being continued indefinitely.
Surgical technique
Follow-up was by clinical examination and duplex ultrasound scanning in the vascular laboratory at 6 Patients were operated upon under general anaesthesia and received antibiotic prophylaxis in the weeks 3, 6, 9 and 12 months after operation and then at variable intervals thereafter. All patients in whom graft occlusion was suspected were investigated further by angiography.
The results, in terms of graft patency and limb salvage, were analysed by calculation of Kaplan-Meier curves, 15 and Log-Rank test was applied to test for statistical significance.
Results
Five patients died within 30 days of operation, giving a perioperative mortality rate of 5.6%. The cumulative survival rate of all patients at 6, 12, and 24 months In the AVF group five grafts occluded within the first month after operation and this was followed by with AVF and controls are shown in Figs 4, 5 and 6. early loss of the limb in four. Another 15 grafts became There was no statistically significant difference beoccluded within the first year, only one of which was tween the two groups with respect to primary and re-explored with restoration of patency. This graft secondary patency rate (p>0.2 Log-Rank test) or limb became occluded again within 14 h. salvage rate (p<0.3 Log-Rank test) at any stage after In the control group 10 grafts occluded within the operation. A trend towards better early patency of first month and this was followed by early amputation grafts with adjuvant AVF diminished progressively in seven. One patient underwent thrombolysis and re-after the first 6 months. exploration with the elective addition of an AVF that restored graft patency for another 6 months. Another 14 grafts in the control group occluded within the first year, two of which were re-explored and one treated Discussion by thrombolysis followed by angioplasty of the inflow vessel (Tables 5, 6 ). A worthwhile period of patency A previously reported study from Liverpool 16 indicated that, although interposition vein-cuff (VC) did was restored in only one of these patients.
The primary and secondary cumulative patency improve the patency rate of long, distal ePTFE grafts in keeping with the findings of the JVRG (Joint Vascular rates and the cumulative limb salvage rate for patients Eur J Vasc Endovasc Surg Vol 17, March 1999 cited as potential complications of adjuvant AVF. In this trial deep veins only were used for the construction of the AVF and patients with a known history of deep vein thrombosis in the relevant limb were excluded. Only two patients developed evidence of clinically significant venous hypertension. It is known that a steal of blood from the foot is likely to occur only if inflow to the graft is impeded 18 and care was taken to ensure that this situation was avoided. Although one patient in the AVF group required amputation despite a patent graft, this was attributable to a large volume of irreversible ischaemia within the foot. No clinical consequences due to steal phenomena were recognised in any of the patients.
Extremely low patency rates, of 30% or less, reported from the use of ePTFE grafts for femoro-infrapopliteal * Adjusted number of patients at risk of the AVF group bypass have fuelled the controversy concerning the * * Adjusted number of patients at risk of the control group relative merits of reconstruction and primary amputation in the absence of autologous vein. However, Research Group) trial, 11 the effect of AVF was rather cumulative patency rates in excess of 50% after the more dubious. A prospectively randomised controlled first year for ePTFE grafts with interposition vein cuff, trial was required to establish whether or not AVF has as reported by the Joint Vascular Research Group of any clinical value.
Great Britain and Ireland 11 and again here, suggest The reported results of autologous vein grafts for that reconstruction is certainly the best option for the femoro-infrapopliteal bypass are considerably majority of patients. However, the results of this trial superior to those of prosthetic grafts including ePTFE. 17 indicate that the addition of AVF confers no worthTherefore, autologous vein is used in preference to while advantage above that which can be achieved ePTFE whenever possible, and this accounts for the with interposition vein cuff alone. Therefore, the apfact that two large vascular surgery units were able to plication of adjuvant AVF as routine is not justified. recruit into this trial only 87 patients in 6 years. The
Many surgeons can report anecdotal experience of relatively small number of patients undermines the having secured worthwhile patency of a graft folpower of the trial and it is possible that a significant lowing early secondary intervention that included the early advantage for AVF, in terms of primary patency, construction of an AVF. One graft in the present series may have been masked by a type two statistical error. remained patent for 6 months under these cirHowever, the observed early trend in favour of AVF cumstances. In this context the following points are diminished progressively after the first 6 months. The worth making; first, harmful effects attributable to rates of limb salvage in AVF and control groups were AVF are rare, and second, the results of this trial cannot very closely matched at all stages after operation. be taken to exclude the possibility that individual Therefore it is probably safe to conclude from the patients may occasionally benefit from the application results of this trial that AVF confers no durable clinical of AVF under exceptional circumstances. benefit.
In summary, the results of this prospectively ranIt would be interesting to know what proportion of domised trial do not show evidence of worthwhile adjuvant A-V fistulae remained patent and whether benefit associated with AVF, in terms of either graft closure of the fistula increased the risk of graft failure. patency or limb salvage rates, and it is concluded, Graft thrombosis was always accompanied by closure therefore, that there is no indication for its routine of the fistula, and it was not possible to determine application with prosthetic femoro-infrapopliteal bywhich occurred first in these circumstances. A small pass grafts. number of grafts have remained patent despite closure of the AVF, but the great majority of patent grafts in the AVF group also had a patent AVF. The absence of References precise information in this respect does not undermine 
